Source comparison
Ipamorelin Half Life: Peptide Comparison Table
Researchers selecting a growth hormone secretagogue must weigh half life against selectivity, potency, and downstream hormone effects. The table below compares ipamorelin to commonly used alternatives based on these criteria. Moderate (300–500% baseline) Highl
This comparison does not assign a generated winner or score.
- Researchers selecting a growth hormone secretagogue must weigh half life against selectivity, potency, and downstream hormone effects. The table below compares ipamorelin to commonly used alternatives based on these criteria.
- Moderate (300–500% baseline)
- Highly selective, no cortisol/prolactin
- Low, suitable for chronic use
- Pulsatile GH studies, body composition, metabolic research
- Best balance of half life, selectivity, and chronic usability for most protocols
- High (400–600% baseline)
- Moderate cortisol/prolactin increase
- Moderate
- Acute GH response studies
- Potent but off-target effects complicate long-term metabolic research
- Significant cortisol/prolactin/appetite increase
- Short-term GH secretion studies
- Strong GH response but appetite stimulation and hormone crosstalk limit utility
- Very High (500–700% baseline)
- Cortisol increase, cardiac effects
- Very High, rapid tachyphylaxis
- Single-dose GH pharmacology studies
- Unsuitable for repeated dosing; desensitization within 2 weeks
- Moderate alone, synergistic with GHRPs
- GHRH receptor selective
- Low
- GHRH/GHRP synergy studies, stacked protocols
- Extends GH pulse duration when stacked, not amplitude; always use with a GHRP
- MK-677
- ~24 hours
- Moderate sustained (200–300% baseline)
- GHS-R1a selective, appetite increase
- Moderate with chronic use
- Oral dosing convenience, continuous GH studies
- Continuous elevation ≠ pulsatile; may impair insulin sensitivity long-term
- The ipamorelin half life of 2 hours strikes the optimal balance. Long enough to produce robust GH secretion with twice-daily dosing, short enough to preserve pulsatile rhythm and avoid receptor desensitization. GHRP-2 and GHRP-6 require 3–4 daily injections due to 30-minute half lives, and both elevate cortisol and prolactin, confounding metabolic and body composition endpoints. Hexarelin's slightly longer half life is offset by rapid desensitization, making it unsuitable for protocols exceeding 10–14 days. MK-677's 24-hour half life offers dosing convenience but produces continuous GH elevation rather than pulses. Emerging evidence suggests this may reduce insulin sensitivity more than pulsatile protocols, a critical consideration in obesity and diabetes research.
- Our Ipamorelin is synthesized to exact amino acid sequencing and supplied as lyophilized powder with >98% purity verified by HPLC and mass spectrometry. Ensuring the pharmacokinetic profile matches published ipamorelin half life data. Researchers working across growth hormone physiology, aging interventions, or neuroendocrine studies can explore additional secretagogues including Hexarelin, Sermorelin, and GHRP-2 through our full peptide collection.